Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

Phase 1

Active, not recruiting

Conditions: Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
HIV Infection
Plasmablastic Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult Non-Hodgkin Lymphoma
Recurrent Burkitt Lymphoma
Recurrent Follicular Lymphoma
Stage III Follicular Lymphoma
Stage III Mantle Cell Lymphoma
Stage IV Follicular Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Biological: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation

First Posted Date: 2016-06-13

Last Posted Date: 2024-07-31

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 11

Registration Number: NCT02797470

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Withdrawn

Conditions: CNS 2a
CNS 2b
CNS 2c
CNS1
Recurrent Adult Acute Myeloid Leukemia
Recurrent Childhood Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Biological: Filgrastim
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: WEE1 Inhibitor AZD1775

First Posted Date: 2016-06-07

Last Posted Date: 2017-05-03

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT02791919

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Cyclophosphamide
Drug: Dasatinib
Drug: Idarubicin
Drug: Idelalisib
Drug: Dexamethasone
Device: In Vitro Kinase Inhibitor Assay
Drug: Doxorubicin Hydrochloride
Drug: Ponatinib Hydrochloride
Drug: Ruxolitinib Phosphate
Drug: Leucovorin Calcium
Drug: Sunitinib Malate
Drug: Methotrexate
Drug: Methylprednisolone Sodium Succinate
Biological: Rituximab
Drug: Sorafenib Tosylate
Drug: Vincristine Sulfate

First Posted Date: 2016-05-20

Last Posted Date: 2020-05-26

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 7

Registration Number: NCT02779283

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

CyBeR Association in Relapsed/Refractory DLBCL

Phase 2

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Bendamustine
Drug: Cytarabine

First Posted Date: 2016-05-03

Last Posted Date: 2016-05-04

Lead Sponsor: University Hospital, Caen

Target Recruit Count: 78

Registration Number: NCT02758925

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Procedure: Bone marrow aspiration
Procedure: Allogeneic stem cell transplant
Procedure: Punch skin biopsy
Device: ClinSeq

First Posted Date: 2016-04-29

Last Posted Date: 2024-10-28

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 107

Registration Number: NCT02756962

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
University of Florida, Gainesville, Florida, United States

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Phase 2

Completed

Conditions: High Grade Malignant Neoplasm
Previously Treated Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Myelodysplastic Syndrome With Excess Blasts-2
Myeloid Neoplasm
Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Chronic Myelomonocytic Leukemia-2
Myelodysplastic Syndrome

Interventions: Drug: Cladribine
Drug: Cyclosporine
Drug: Cytarabine
Biological: Filgrastim
Drug: Fludarabine Phosphate
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mitoxantrone Hydrochloride
Drug: Mycophenolate Mofetil
Other: Questionnaire Administration
Drug: Sirolimus
Radiation: Total-Body Irradiation
Drug: Melphalan Hydrochloride

First Posted Date: 2016-04-29

Last Posted Date: 2021-11-08

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT02756572

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

Phase 1

Completed

Conditions: B-cell Lymphoma

Interventions: Drug: selinexor
Drug: Rituximab
Drug: Dexamethasone
Drug: Oxaliplatin
Drug: Cisplatin
Drug: Cytarabine
Drug: Gemcitabine

First Posted Date: 2016-04-18

Last Posted Date: 2021-12-07

Lead Sponsor: The Lymphoma Academic Research Organisation

Target Recruit Count: 39

Registration Number: NCT02741388

Locations: 🇫🇷
CHU Dijon, Dijon, France
🇫🇷
CHRU de Lille - Hôpital Claude Huriez, Lille, France
🇧🇪
Institut Jules Bordet, Bruxelles, Belgium

and more 5 locations

Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Phase 1

Completed

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Bendamustine
Drug: Rituximab
Drug: Cytarabine
Drug: Pegfilgrastim
Procedure: Leukapheresis
Drug: Filgrastim
Procedure: Autologous stem cell transplant

First Posted Date: 2016-04-05

Last Posted Date: 2023-11-01

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 18

Registration Number: NCT02728531

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Acute Myeloid Leukemia
de Novo Myelodysplastic Syndrome
Acute Biphenotypic Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Drug: Mitoxantrone
Drug: Sorafenib

First Posted Date: 2016-04-05

Last Posted Date: 2023-07-05

Lead Sponsor: University of Washington

Target Recruit Count: 84

Registration Number: NCT02728050

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: Leukemia

Interventions: Drug: Ruxolitinib
Drug: Asparaginase Erwinia Chrysanthemi
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin
Drug: Leucovorin Calcium
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Pegaspargase
Drug: Prednisone
Drug: Thioguanine
Drug: Vincristine Sulfate

First Posted Date: 2016-03-31

Last Posted Date: 2024-11-29

Lead Sponsor: Incyte Corporation

Target Recruit Count: 171

Registration Number: NCT02723994

Locations: 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Texas Childrens Hospital, Houston, Texas, United States

and more 105 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy